Viewing Study NCT05241093


Ignite Creation Date: 2025-12-25 @ 12:58 AM
Ignite Modification Date: 2026-01-02 @ 2:41 AM
Study NCT ID: NCT05241093
Status: RECRUITING
Last Update Posted: 2025-04-10
First Post: 2022-01-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor: Tarapeutics Science Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module